

BRAND ACCESS

Marketplace Dynamics: Multiple Sclerosis

Marketplace Dynamics: Multiple Sclerosis assesses current and future access and prescribing landscapes for multiple sclerosis drugs, supporting identification of opportunities and risks for brands.

- What level of influence do payers and organized providers have on access in the multiple sclerosis treatments market?
- How will payer and organized provider management and contracting for branded multiple sclerosis drugs evolve over the next two years, and how should clients prepare for these changes?
- How are payers responding to key events in the multiple sclerosis drugs market, such as new approvals and updated clinical data?

Use **Marketplace Dynamics: Multiple Sclerosis** to:

- Closely monitor market evolution
- Recognize shifts in relative influence of payers and organized providers on access
- Assess and predict current and future payer management of the multiple sclerosis drugs market to develop effective strategies for inline/pipeline brand(s)
- Identify risks for brands, along with opportunities to improve access

Brand Access Influencers and Management Landscape—Multiple Sclerosis March	<ul style="list-style-type: none"> • Road map for improving access for branded multiple sclerosis drugs in 2021 • Analysis of stakeholder approaches to prioritizing and managing the multiple sclerosis drugs market • Payer use of reimbursement, cost sharing, and utilization management tactics to influence use and restrict access of multiple sclerosis drug market • Brand-specific line-of-therapy requirements across multiple sclerosis indications • Evolving management strategies for brands on the medical benefit, and evolving site-of-care management • Role of PBMs and specialty pharmacies (SPs) on product selection, distribution, and management
Organized Provider Management and Evolving Payment Models—Multiple Sclerosis May	<ul style="list-style-type: none"> • Organized provider use of management tools and tactics to influence drug use and specialist treatment decisions • Brand-specific line-of-therapy requirements across multiple sclerosis indications • Prevalence of alternative payment models, innovative financial incentives, and performance metrics, along with associated impacts on drug access
Contracting Trends and Insights—Multiple Sclerosis July	<ul style="list-style-type: none"> • Impact and prevalence of contracting in the multiple sclerosis drugs market • Key contracting terms and success factors driving access gains for branded multiple sclerosis drugs • Evolution of risk-based contracting agreements for branded multiple sclerosis drugs
Outlook on Brand Access in 2024—Multiple Sclerosis September	<ul style="list-style-type: none"> • Evolution of access in the branded multiple sclerosis drugs market • Predicted management tactics for multiple sclerosis drugs at payers and organized providers by 2024 • Brand access predictions reflecting in-depth future scenarios with high likelihood of occurring

This product may also include relevant market alerts, real-time assessments of recent changes, or discussions of market events. EVERSANA reserves the right to change the timing and/or topics of its syndicated research publications.

Visit: www.EVERSANA.com Phone: 609.397.5282 Email: HSIclientservices@EVERSANA.com